MedTrace Logo

Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis

NCT01932372 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9968

Last updated 2024-10-26

Study results available
· View outcomes & findings →

Summary

The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice.

1\) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2） Long-term safety (particularly, malignant tumors and serious infections) and efficacy

Occurrences of malignant tumors and serious infections will be compared with a control group.

Conditions

Interventions

DRUG

Tofacitinib (Xeljanz)

5 mg Tablet BID

DRUG

Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc

Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-26
Primary Completion
2021-08-24
Completion
2021-08-24

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01932372 on ClinicalTrials.gov